CorMedix (CRMD) is presenting its Q4 2025 earnings preview, a key event for the stock following a significant guidance reset and a recent buyback authorization.
Source Post
CorMedix $CRMD Q4 2025 Earnings Preview
Mar 15, 2026
CorMedix (CRMD) is set to report Q4 2025 earnings, a critical event following a recent guidance reset. The company, focused on infectious diseases with its product Defencath and a diversified portfolio from the Melinta acquisition, faces scrutiny on its 2027 rebound strategy and buyback program. Analysts remain largely positive, with a consensus strong buy rating and a target price significantly above the current trading level, despite recent analyst estimate revisions and a high short interest.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.